The Times Australia
Fisher and Paykel Appliances
News From Asia

.

Zuellig Pharma unveils state-of-the-art Clinical Trial Support Innovation Center in South Korea to support both domestic and global clinical research needs

New facility is set to be South Korea’s most advanced automated hub for clinical logistics and sourcing, reinforcing the nation’s position as a leader in clinical research innovation

GYEONGGI-DO, SOUTH KOREA - Media OutReach Newswire - 1 December 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, today announced the grand opening of its new state-of-the-art Clinical Trial Support (CTS) Innovation Center in South Korea.

The opening of this facility underscores Zuellig Pharma's continued investment and commitment to advancing healthcare, reinforcing its position as a trusted regional partner in driving meaningful outcomes for patients, partners, and communities across the region.

Strategically located near the Gyeongbu Expressway in Gyeonggi-do province, the new 3,800-square-meter facility is set to redefine standards in clinical trial logistics through automation, digitalization, and stringent Good Practice (GxP) compliance. It is designed to enhance operational efficiency, scalability, and reliability across diverse therapeutic areas.

"As part of an integrated healthcare solutions company, this milestone marks a significant step forward for Zuellig Pharma in remaining agile and responsive to the evolving clinical trial landscape. It also reflects Zuellig Pharma's continued commitment to advancing healthcare through innovation and sustainable infrastructure, creating greater access to treatments and delivering meaningful outcomes for partners and communities we serve," said John Graham, CEO of Zuellig Pharma.

The facility is equipped with advanced capabilities that set new standards for clinical trial logistics. It features a fully automated order fulfillment system that enhances the speed, accuracy, and reliability of clinical supply delivery. Its flexible and scalable architecture ensures uninterrupted operations, while robust cybersecurity measures safeguard sensitive clinical trial data.

In addition, the facility provides comprehensive temperature-zone support, enabling Zuellig Pharma to manage thousands of unique clinical trial SKUs under strict ambient, cold, frozen, deep frozen, cryogenic and return storage conditions. This ensures that temperature-sensitive products are handled with the highest level of precision throughout the entire supply chain.

Designed with precision, the facility's specialized repackaging infrastructure is built to accommodate controlled environments tailored to ambient, cold, frozen, and amber light repackaging specifications. These environments meet stringent clinical and regulatory standards, ensuring product integrity is maintained throughout the clinical trial lifecycle. Furthermore, an integrated end-to-end tracking and monitoring system provides full chain-of-custody, complete traceability, and adherence to GxP requirements, reinforcing quality and compliance at every stage.

"As of 2025, South Korea ranks among the world's top 10 clinical trials markets and holds the third-largest number of R&D pipelines globally. Our new facility has been built to meet this rising demand, redefining how investigational products are stored, managed, and distributed. With precision in mind, we aim to enable the reliable delivery of critical therapies to improve patient access and outcomes worldwide," added Giuseppe Leo, SVP, Clinical Trial Support Business Unit Lead, Zuellig Pharma.

Over the past year, the center has supported over 3,000 cumulative studies in collaboration with more than 100 clients, managing an annual volume of approximately 13,000 outbound shipments, including chemical, biologics, medical devices and cellular and gene therapies. Its extensive track record includes partnerships with 14 of the world's top 20 pharmaceutical companies and 8 of the top 10 global CROs, underscoring its position as a trusted partner in global clinical trial research.

Hashtag: #ZuelligPharma #ClinicalTrials #Automation #Healthcare #Pharmaceuticals #ColdChain #Logistics



The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Times Magazine

Seven in Ten Australian Workers Say Employers Are Failing to Prepare Them for AI Future

As artificial intelligence (AI) accelerates across industries, a growing number of Australian work...

Mapping for Trucks: More Than Directions, It’s Optimisation

Daniel Antonello, General Manager Oceania, HERE Technologies At the end of June this year, Hampden ...

Can bigger-is-better ‘scaling laws’ keep AI improving forever? History says we can’t be too sure

OpenAI chief executive Sam Altman – perhaps the most prominent face of the artificial intellig...

A backlash against AI imagery in ads may have begun as brands promote ‘human-made’

In a wave of new ads, brands like Heineken, Polaroid and Cadbury have started hating on artifici...

Home batteries now four times the size as new installers enter the market

Australians are investing in larger home battery set ups than ever before with data showing the ...

Q&A with Freya Alexander – the young artist transforming co-working spaces into creative galleries

As the current Artist in Residence at Hub Australia, Freya Alexander is bringing colour and creativi...

The Times Features

Why a Holiday or Short Break in the Noosa Region Is an Ideal Getaway

Few Australian destinations capture the imagination quite like Noosa. With its calm turquoise ba...

How Dynamic Pricing in Accommodation — From Caravan Parks to Hotels — Affects Holiday Affordability

Dynamic pricing has quietly become one of the most influential forces shaping the cost of an Aus...

The rise of chatbot therapists: Why AI cannot replace human care

Some are dubbing AI as the fourth industrial revolution, with the sweeping changes it is propellin...

Australians Can Now Experience The World of Wicked Across Universal Studios Singapore and Resorts World Sentosa

This holiday season, Resorts World Sentosa (RWS), in partnership with Universal Pictures, Sentosa ...

Mineral vs chemical sunscreens? Science shows the difference is smaller than you think

“Mineral-only” sunscreens are making huge inroads[1] into the sunscreen market, driven by fears of “...

Here’s what new debt-to-income home loan caps mean for banks and borrowers

For the first time ever, the Australian banking regulator has announced it will impose new debt-...

Why the Mortgage Industry Needs More Women (And What We're Actually Doing About It)

I've been in fintech and the mortgage industry for about a year and a half now. My background is i...

Inflation jumps in October, adding to pressure on government to make budget savings

Annual inflation rose[1] to a 16-month high of 3.8% in October, adding to pressure on the govern...

Transforming Addiction Treatment Marketing Across Australasia & Southeast Asia

In a competitive and highly regulated space like addiction treatment, standing out online is no sm...